Haematology 2018

PHEONIX Clinical Study Design: Double blind randomised phase III

6 x R-CHOP21 + ibrutinib

Non-GC

R

6 x R-CHOP21 + Placebo

Select by IHC

DLBCL

* Option for 2 additional rituximab doses after completing treatment regimen (if considered standard of care per local practice )

GC

Ineligible

▪ Newly diagnosed DLBCL of non-GC ▪ ECOG PS ≤ 2; Age 18–80 ▪ Primary Endpoint = EFS ▪ N = 800

ClinicalTrials.gov.NCT02285062